Medical Therapy. Adverse Effects or Lack of Adverse Effects

Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study

Dunbar Ivy, Maurice Beghetti, Ernesto Juaneda‑Simian, Ramiya Ravindranath, Mary Ann Lukas, Sandra Machlitt‑Northen, Nicola Scott, Jun Narita, Rolf M. F. BergerChildren’s Hospital Colorado. University Children’s Hospital HUG and University of Geneva. Hospital de Niños de la Santísma Trinidad. Glaxo-Smith-Kline. Osaka University Graduate School of Medicine. Beatrix Children’s Hospital, University Medical Center Groningen and University of […]

Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study Read More »

Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia

Shino Yoshida, Olivia Eichelberger, Michael Ulis, Alexander M. Kreger, George K. Gittes, Joseph T. ChurchUniversity of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh. University of Michigan Medical School.United States Pediatric SurgeryPediatr Surg 2024;DOI: 10.1016/j.jpedsurg.2024.01.010 AbstractBackground: Pulmonary hypertension remains difficult to manage in congenital diaphragmatic hernia (CDH). Prenatal therapy may ameliorate postnatal pulmonary hypertension. We

Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia Read More »

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach

Satyan Lakshminrusimha, Steven H. AbmanUniversity of California, Davis Children’s Hospital. University of Colorado Anschutz Medical Campus.United States Clinics in PerinatologyClin Perinatol 2024; 51: 77-94DOI: 10.1016/j.clp.2023.12.003 AbstractOxygen is a specific pulmonary vasodilator. Hypoxemia causes pulmonary vasoconstriction, and normoxia leads to pulmonary vasodilation. However, hyperoxia does not enhance pulmonary vasodilation but causes oxidative stress. There are no clinical

Oxygen Targets in Neonatal Pulmonary Hypertension: Individualized, “Precision-Medicine” Approach Read More »

Vasopressin in newborns with refractory acute pulmonary hypertension

Simon Ouellet, Christine Drolet, Genevéve Morissette, Annie Pellerin, Audrey HébertCHU de Québec, Université Laval. Canada Pediatric ResearchPediatr Res 2024;DOI: 10.1038/s41390-023-02995-3 AbstractBackground: Acute pulmonary hypertension (aPH) in newborns can be life threatening and challenging to manage. In newborns with refractory aPH, there is currently limited therapeutic agents.Methods: Retrospective single-center cohort study in newborns less than one month old who

Vasopressin in newborns with refractory acute pulmonary hypertension Read More »

Reversible severe pulmonary hypertension related to scurvy in children

Marin Satawiriya, Apichai Khongphatthanayothin, Alisa LimsuwanFaculty of Medicine Ramathibodi Hospital and Mahidol University. Bangkok Heart Hospital. Chulalongkorn University. Thailand BioMed Central Cardiovascular DisordersBMC Cardiovasc Disord 2024; 24:DOI: 10.1186/s12872-023-03629-6 AbstractBackground: Severe pulmonary hypertension (PH) in childhood is rare and can manifest as a life-threatening episode. We present 2 children with restrictive dietary habits with severe pulmonary hypertension secondary

Reversible severe pulmonary hypertension related to scurvy in children Read More »

Use of Metformin in Pulmonary Vein Stenosis after TAPVR Repair

Edward C. Kirkpatrick, Michael E. Mitchell, MD, William G. Thilly, Joseph Cava, Aoy Tomita-Mitchell, Elena V. GostjevaChildren’s Hospital of Wisconsin and Medical College of Wisconsin. Massachusetts Institute of Technology. United States Global Pediatric HealthGlob Pediatr Health 2020;DOI: 10.1177/2333794X20958924 AbstractAbstract Not Available CategoryClass II. Pulmonary Hypertension Associated with Pulmonary Vein StenosisMedical Therapy. Efficacy or Lack of EfficacyMedical Therapy. Adverse Effects or Lack of Adverse Effects Age Focus: Pediatric Pulmonary

Use of Metformin in Pulmonary Vein Stenosis after TAPVR Repair Read More »

A prospective phase II trial of vinblastine and methotrexate in multivessel intraluminal pulmonary vein stenosis in infants and children

Maliha Rehman, Kathy J. Jenkins, Amy L. Juraszek, Jean A. Connor, Kimberlee Gauvreau, Muhammad Muneeb, Laureen M. Sena, Steven D. Colan, Terry Saia, Mark W. KieranChildren’s Hospital, Boston.United States Congenital Heart DiseaseCongenit Heart Dis 2011; 6: 608-623DOI: 10.1111/j.1747-0803.2011.00574.x AbstractObjective: To determine the safety and efficacy of the chemotherapeutic agents vinblastine and methotrexate in the treatment of children

A prospective phase II trial of vinblastine and methotrexate in multivessel intraluminal pulmonary vein stenosis in infants and children Read More »

Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review

Meng Li, Lin Liu, Cong Liu, Zebin Chen, Weibin Li, Xuejuan Li, Xiaopeng Ma, Yumao ZhangShenzhen Children’s Hospital. Eighth Affiliated Hospital and Sun Yat-sen University.China Clinical TherapeuticsClin Ther 2023; DOI: 10.1016/j.clinthera.2023.09.026 AbstractPurpose: To systematically evaluate the safety, dosing regimen, and efficacy of selexipag for pediatric patients with pulmonary hypertension (PH).Methods: A literature search of the electronic databases of

Selexipag for the Treatment of Pediatric Pulmonary Hypertension: A Systematic Review Read More »

Rapidly Progressive Idiopathic Pulmonary Arterial Hypertension in a Paediatric Patient Treated with Lung Transplantation

Filip Baszkowski, Weronika Pelczar-Płachta, Nikola Pempera, Sylwia Sławek-Szmyt, Marta Kałuzna-Oleksy, Maciej Lesiak, Waldemar BobkowskiPoznan University of Medical Sciences.Poland DiagnosticsDiagnostics 2023; DOI: 10.3390/diagnostics13203185 AbstractPulmonary arterial hypertension (PAH) is a rare heterogeneous disorder in the paediatric population which is mostly associated with congenital heart disease. The management of paediatric idiopathic PAH (IPAH) is difficult due to insufficient comparative

Rapidly Progressive Idiopathic Pulmonary Arterial Hypertension in a Paediatric Patient Treated with Lung Transplantation Read More »

Home-inhaled nitric oxide in a child with pulmonary arterial hypertension associated with post-operative pulmonary venous obstruction

Yuichiro Sugitani, Jun Muneuchi, Mamie WatanabeKyushu Hospital and Japan Community Healthcare Organization.Japan Cardiology in the YoungCardiol Young 2023; DOI: 10.1017/S1047951123003591 AbstractHome-inhaled nitric oxide therapy was effective and feasible in the patients with intractable pulmonary arterial hypertension. We present the case of a child with severe pulmonary arterial hypertension associated with post-operative pulmonary venous obstruction who was

Home-inhaled nitric oxide in a child with pulmonary arterial hypertension associated with post-operative pulmonary venous obstruction Read More »

Scroll to Top